Autoimmune Hepatitis clinical trials at University of California Health

3 in progress, 1 open to eligible people

Showing trials for

  • Liver Cirrhosis Network Cohort Study

    open to eligible people ages 18 years and up

    Liver Cirrhosis Network (LCN) Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months (180 days), with opportunities to complete specific visit components via telehealth or remotely. Visits will include collection of questionnaire data and the in-person visits will include questionnaires, physical exams, imaging, and sample collection.

    at UCSD UCSF

  • ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

    Sorry, in progress, not accepting new patients

    VAY736 dose testing; VAY736 efficacy and safety testing.

    at UC Davis

  • Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

    Sorry, in progress, not accepting new patients

    This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

    at UCLA UCSF

Last updated: